The decision-making process of us food and drug administration advisory committees on switches from prescription to over-the-counter status: A comparative case study

Clinical Therapeutics

Volumn 28, Issue 8, 2006, Pages 1231-1243

  Nguyen, Nancy Thai ^a   Cook, Daniel M ^a   Bero, Lisa A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

emergency oral contraceptive; FDA; health policy; nicotine replacement; OTC; over the counter switch; statins

Indexed keywords

DRUG; LEVONORGESTREL; MEVINOLIN; NICOTINE GUM; NON PRESCRIPTION DRUG; ORAL CONTRACEPTIVE AGENT; PRAVASTATIN; UNCLASSIFIED DRUG;

ADVISORY COMMITTEE; ARTICLE; COMPARATIVE STUDY; DECISION MAKING; DRUG COST; DRUG EFFICACY; DRUG SAFETY; EMERGENCY CONTRACEPTION; FOOD AND DRUG ADMINISTRATION; NICOTINE REPLACEMENT THERAPY; ORAL CONTRACEPTION; PRESCRIPTION; PRESCRIPTION DRUG; PUBLICATION; VIDEORECORDING;

EID: 33748593352     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2006.08.007     Document Type: Note

References (46)

1. Ashford N.A. Advisory committees in OSHA and EPA: Their use in regulatory decision-making. Sci Technol Hum Values 9 (1984) 72-82
2. Sherman L.A. Looking through a window of the Food and Drug Administration: FDA's advisory committee system. Preclinica 2 (2004) 99-102
3. January 1995 FDA Consumer Special Report. Available at:. Farley D. Getting outside advice for 'close calls'. Accessed April 12 (2005). http://www.fda.gov/fdac/special/newdrug/advice.html
4. In: Rettig R.A., Earley L.E., and Merrill R.A. (Eds). Food and Drug Administration Advisory Committees/Committee to Study the Use of Advisory Committees by the Food and Drug Administration (1992), National Academy Press, Washington, DC
5. Center for Drug Evaluation and Research committees. http://www.fda.gov/oc/advisory/acdrugs.htm1. Accessed June 29, 2005.
6. FDA. About CIDER. Who we are and what we do. http:// www.fda.gov/cder/about/default.htm. Accessed June 29, 2005.
7. Juhl R.P. Prescription to over-the-counter switch: A regulatory perspective. Clin Ther 20 Suppl C (1998) C111-Cl17
8. January 26. Consumer Healthcare Products Association. Ingredients & dosages transferred from Rx-to-OTC status (or new OTC approvals) by the Food and Drug Administration since 1975. Accessed March 10, 2006 (2006). http://www.chpa/info.org/NR/rdonlyres/E33F414C Accessed March 10, 2006
9. Report OEI-01-01-00590. US Dept of Health and Human Services, Office of the Inspector General. FDA's Review Process for New Drug Applications: A Management Review (March 2003), Office of Inspector General, Washington, DC
10. Accessed October 27. US Food and Drug Administration, Center for Drug Evaluation and Research. Office of Nonprescription Products (2004). http://www.fda.gov/cder/offices/otc/default.htm
11. Glode E.R. Advising underthe influence? Conflicts of interest among FDA advisory committee members. Food Drug Law J 57 (2002) 293-322
12. Juhl R.P. An interpretive guide to chairing an FDA advisory committee. 1997. Food Drug Law J 52 (1997) 133-140
13. March 5. Sasich L.I.D., Wolfe S.M., and Public Citizen Health Research Group. Comments on Disclosure of Conflicts of Interest for Special Government Employees Participating in FDA Product Specific Advisory Committees: Draft Guidance (HRG Publication #1612). Accessed October 18 (2002-2004). http://www.publiccitizen.org/publications/printrelease.cfm?ID=7157
14. Available at:. US General Services Administration. The Federal Advisory Committee Act with amendments and annotations. Accessed February 5 (2005). http://www.gsa.gov/gsa/cmattachments/GSA_BASIC/with_annotations_R2G_64T_ OZ5RDZ
15. Available at:. US Food and Drug Administration, Center for Devices and Radiological Health. Code of Federal Regulations Title 21-Food and Drugs, Chapter I, Subchapter A, Part 14-Public Hearing Before a Public Advisory Committee. Accessed June 29 (2004). http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCFR/CFRSearch.cfm?CF RPart=14&showFR=1
16. Solomon D.H., and Avorn J. Coxibs, science, and the public trust. Arch Intern Med 165 (2005) 158-160
17. March 10. Center for Science in the Public Interest. Health advocates urge reform of FDA advisory committees: Scientists shouldn't be passing judgment on their funders' products, groups say. Accessed June 29, 2005 (2005). http://cspinet.org/new/200503101.html Accessed June 29, 2005
18. February 25. Center for Science in the Public Interest. Conflicts of interest on COX-2 panel: Research from CSPI's Integrity in Science Project. Accessed June 29, 2005 (2005). http://cspinet.org/integrity/press/200502251.html Accessed June 29, 2005
19. February 20. Gorman C. Can the FDA heal itself? A permanent director and a new safety panel may not be enough to bring the agency back to health. Time (2005)
20. Lurie P., Almeida C.M., Stine N., et al. Financial conflict of interest disclosure and voting patterns at Food and Drug Administration Drug Advisory Committee meetings. JAMA 295 (2006) 1921-1928
21. Brass E.P. Changing the status of drugs from prescription to over-the-counter availability. N Engl J Med 345 (2001) 810-816
22. Soller W.R. Prescription-to-over-thecounter switch criteria. Drug Inf J 36 (2002) 309-317
23. Lipsky M.S., and Waters T. The "prescription-to-OTC switch" movement: Its effects on antifungal vaginitis preparations. Arch Fam Med 8 (1999) 297-300
24. Accessed June 15. Committee Charter. Nonprescription Drugs Advisory Committee (2004). http://www.fda.gov/cder/audiences/acspage/Nonprescriptioncharterl.htm
25. July 13. US Food and Drug Administration, Center for Drug Evaluation and Research. Accessed May 15, 2006. Joint Meeting of the Nonprescription Drugs Advisory Committee and the Endocrinologic and Metabolic Advisory Committee (2000). http://www.fda.gov/ohrms/dockets/ac/00/transcripts/3622tl.rtf Accessed May 15, 2006
26. July 14. US Food and Drug Administration, Center for Drug Evaluation and Research. Accessed May 15, 2006. Joint Meeting ofthe Nonpre scription Drugs Advisory Committee and the Endocrinologic and Metabolic Advisory Committee (2000). http://www.fda.gov/ohrms/dockets/ac/00/transcripts/3622t2.rtf Accessed May 15, 2006
27. December 16. US Food and Drug Administration, Center for Drug Evaluation and Research. Nonprescription Drugs Advisory Committee (NDAC) in Joint Session with the Advisory Committee for Reproductive Health Drugs (ACHRD). Accessed May 15 (2003-2006). http://www.fda.gov/ohrms/dockets/ac/03/transcripts/4015Tl.doc. Accessed May 15
28. Center for Drug Evaluation and Research Joint Meeting. Nonprescription and Drug Abuse Advisory Committee (1995), US Food and Drug Administration, Rockville, Md
29. January 13. US Food and Drug Administration, Center for Drug Evaluation and Research. Joint Meeting of the Nonprescription Drugs Advisory Committee and the Endocrinologic and Metabolic Advisory Committee. Non-Prescription Mevacor® 20 mg (2005)
30. Glaser B.G. Theoretical Sensitivity: Advances in the Methodology of Grounded Theory (1978), Calif Sociology Press, Mill Valley
31. Yin R.K. Case Study Research: Design and Methods. 3rd ed. (2003), Sage Publications, Thousand Oaks, Calif
32. Washington, DC: November. United States Government Accountability Office Report to Congressional Requesters. Food and Drug Administration Decision Process to Deny Initial Application for Over-the-Counter Marketing of the Emergency Contraceptive Drug Plan B Was Unusual. Report GAO-06-109 (2005)
33. Letter from Dr. Steven Galson, Acting Director, Center for Drug Evaluation and Research, US Food and Drug Administration, to Dr. Joseph A. Carrado, Senior Director, Regulatory Affairs, Barr Research, Inc. May 6, 2004.
34. Brushwood D.B., and Abood R.R. A third class of drugs: An overview. Drug Intell Clin Pharm 19 (1985) 62-66
35. Balla S.J., and Wright J.R. Interest groups, advisory committees, and congressional control of the bureaucracy. Am J Pol Sci 45 (2001) 799-812
36. Chess C., and Purcell K. Public participation and the environment: Do we know what works?. Environ Sci Technol 33 (1999) 2685-2692
37. McComas K.A., Tuite L.S., and Sherman L.A. Conflicted scientists: The "shared pool" dilemma of scientific advisory committees. Public Understanding Sci 14 (2005) 285-303
38. September 25. Cauchon D. FDA advisors tied to industry. USA Today (2000)
39. January-February. Rados C. Advisory committees: Critical to the FDA's product review process. FDA Consumer (2004)
40. Bruch M.K., and Larson E. An early historical perspective on the FDA's regulation of OTC drugs. Infect Control Hosp Epidemiol 10 (1989) 527-528
41. August 28. Harris G. Drugs, politics and the F.D.A. The New York Times (2005)
42. Dresser R. Plan B: Politics and values at the FDA, again. Hastings Cent Rep 34 (2004) 9-10
43. September 1. Harris G. Official quits on pill delay at the F.D.A. The New York Times (2005)
44. September 24. Kaufman M. FDA Commissioner steps down after rocky two-month tenure. The Washington Post (2005)
45. Pharmacy Access Partnership. EC over-the-counter (OTC) status (2006). http://www.pharmacyaccess.org/ecotcstatus.htm
46. Francis S.A., Barnett N., and Denham M. Switching of prescription drugs to over-the-counter status: Is it a good thing for the elderly?. Drugs Aging 22 (2005) 361-370